Amneal Pharmaceuticals Inc at Piper Sandler Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: David Amsellem - Piper Sandler - Analyst : But delighted to have you here and certainly lots to talk about and we'll just dive right in. Let's start with CREXONT, which was approved earlier this year and is launched and it's a pretty important brand product for the company. So I wanted to pick your brain on just your overall commercial strategy for the product and Parkinson's and how differently is it being positioned relative to Rytary?

Question: David Amsellem - Piper Sandler - Analyst : You mean general. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 04, 2024 / 4:00PM, AMRX.OQ - Amneal Pharmaceuticals Inc at Piper Sandler Healthcare Conference

Question: David Amsellem - Piper Sandler - Analyst : So a few follow up questions about the product. So we all know right, is losing exclusivity next year. So I think one of the big questions is okay, CREXONT is growing, but you do have the loss of Atari. What does your Parkinson's franchise footprint sales footprint look like in '25 versus this year?

Question: David Amsellem - Piper Sandler - Analyst : Okay. That's helpful. So you mentioned, good payer access so far. I guess looking ahead though, and I realize CREXONT is a different product than Rytary. But -- and when there is a generic for Rytary, how do you see the payer landscape changing if at all?

Question: David Amsellem - Piper Sandler - Analyst : That that's a good point. Okay. So let's talk more broadly about brand assets. So and I know you get this question a lot. So but I have to ask it just how much of a priority is in licensing and acquisitions of a brand asset here and there. And what's your capacity in terms of how big you can go?

Question: David Amsellem - Piper Sandler - Analyst : Most of the brand assets you're looking at in neurology or are you thinking about --

Question: David Amsellem - Piper Sandler - Analyst : Yes.

Question: David Amsellem - Piper Sandler - Analyst : Okay. So in terms of [Biz] Dev, neuro and oncology are --

Question: David Amsellem - Piper Sandler - Analyst : You did have some recent developments on the DHE auto injector. And so maybe just walk us through, that product and that opportunity I mean, DHE is a good product for migraine. So help us understand how you're thinking about it.

Question: David Amsellem - Piper Sandler - Analyst : And do you have a commercial infrastructure in place? Do you need to add head count to support that product? So migraine specialists.

Question: David Amsellem - Piper Sandler - Analyst : Reallocate those.

Question: David Amsellem - Piper Sandler - Analyst : Okay and speaking of unit authority, I mean that that's grown fairly significantly. So help us understand why that has been a growth product for you. Given that levothyroxine is -- there are generics in the market is a unique market, but what's been the driver of continued volume growth there?

Question: David Amsellem - Piper Sandler - Analyst : Right? And there are even though there are generics, I mean to your point, the because the dosing is so individualized and go carefully --

Question: David Amsellem - Piper Sandler - Analyst : Let's move on to injectables. So that's obviously a growing part of the business. Remind us what the current top line contribution is for generic injectables this year. And just in general, what's your aspirational goal in terms of number of launches of injectables annually?

Question: David Amsellem - Piper Sandler - Analyst : So you've talked about shortage products and also you're focused on complex injectables as well. I guess my question here is as you look over the next sort of one year to two years is more of the growth going to be coming from more complex products or is it going to be coming from shortage products? It's going to be more complex.

Question: David Amsellem - Piper Sandler - Analyst : And in terms of capacity, are you right size? How much more capacity --

Question: David Amsellem - Piper Sandler - Analyst : In terms of the generics pipeline broadly speaking. Can you talk to your evolution away from oral solids and talk through your pipeline right now in terms of how much of the pending and as are not oral solids, obviously, it's been, that's been a big change in Amy all over the last few years, but maybe help us better understand where you are right now.

Question: David Amsellem - Piper Sandler - Analyst : These are filed products.

Question: David Amsellem - Piper Sandler - Analyst : And actually, that's a good way to segue into your biosimilars business. So you have three. Can you talk to the current top line contribution from the three biosims you have on the on the market and how you see the aggregate opportunities for the three that have asked the last and (inaudible)

Question: David Amsellem - Piper Sandler - Analyst : 8 to 10, that are currently partnered. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 04, 2024 / 4:00PM, AMRX.OQ - Amneal Pharmaceuticals Inc at Piper Sandler Healthcare Conference

Question: David Amsellem - Piper Sandler - Analyst : What does that mean for you guys in terms of CapEx and deployment of cash resources to get to vertical integration and biosimilars?

Question: David Amsellem - Piper Sandler - Analyst : That's helpful. That's helpful and understanding the [CapEx].

Question: David Amsellem - Piper Sandler - Analyst : And you know, biosimilars broadly speaking, are just not going to have the kind of commoditization that you'd see with oral generics, different.

Question: David Amsellem - Piper Sandler - Analyst : So let's talk about Metsera. And GLP-1 and but maybe first just talk about the collaboration and I think there's, one product here, MET097. So maybe talk about that, the collaboration and that and that product. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 04, 2024 / 4:00PM, AMRX.OQ - Amneal Pharmaceuticals Inc at Piper Sandler Healthcare Conference

Question: David Amsellem - Piper Sandler - Analyst : In terms of your overall GLP-1 strategy, and I realize there's probably not a ton you can talk about here but you've got [Lyro Glut].

Question: David Amsellem - Piper Sandler - Analyst : So that's another one. That's another one.

Question: David Amsellem - Piper Sandler - Analyst : So to be clear, all of the usual suspects.

Question: David Amsellem - Piper Sandler - Analyst : But, and looking at -- I know [Trulicity] is one that's interesting because it's, I think it's a 2027 electivity. But so that's, that's one that you're, I know you're not disclosing where you are. But let's assume that is it safe to assume you're going to be a market participant. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 04, 2024 / 4:00PM, AMRX.OQ - Amneal Pharmaceuticals Inc at Piper Sandler Healthcare Conference

Question: David Amsellem - Piper Sandler - Analyst : And then just lastly very quick question, I know we started late. So I'm going to -- I'm going to -- give me one more but just the outcare business.

Question: David Amsellem - Piper Sandler - Analyst : I guess it's a little bit of a different business. So is it a core part of amneal?